BioViva Science

BioViva Science is a private, pre-clinical stage biotech firm targeting the biology of aging as a therapeutic area. The company is developing a dual-platform gene therapy approach, utilizing established AAV vectors and a proprietary CMV-based platform designed for larger genetic payloads to address complex, multi-factorial age-related diseases. While presenting an ambitious vision for treating cellular aging itself, the company appears to be in an early development and fundraising stage, with its primary public-facing asset being an open-access gene therapy database called CodeKeeper™.

Dual viral vector gene therapy platform utilizing AAV (Adeno-Associated Virus) for proven delivery and a proprietary CMV (Cytomegalovirus)-based platform designed to carry larger genetic payloads for complex multi-gene therapies targeting cellular aging.

BioViva operates in the emerging longevity therapeutics space, competing with other biotechs like Unity Biotechnology, Calico (Alphabet), and Altos Labs, as well as gene therapy companies developing treatments for specific age-related diseases. Its claimed CMV platform for large payloads is a differentiating technological angle, but it competes in a high-risk, high-capital environment against well-funded entities.